miR-573 inhibits prostate cancer metastasis by regulating epithelialmesenchymal transition

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35978-35990

  Wang, Lin ^a   Song, Guanhua ^a   Tan, Weiwei ^b   Qi, Mei ^b   Zhang, Lili ^b   Chan, Jonathan ^c   Yu, Jindan ^d   Han, Jinxiang ^a   Han, Bo ^b,e  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d NORTHWESTERN UNIVERSITY   (United States)

^e SHANDONG UNIVERSITY   (China)

Author keywords

FGFR1; GATA3; Metastasis; MiR 573; Prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MICRORNA; MICRORNA 573; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; MIRN573 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FGF2 GENE; FGFR1 GENE; GATA GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENETIC REGULATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR INVASION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BAGG ALBINO MOUSE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SECONDARY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 84946854584     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5427     Document Type: Article

References (32)

1. Hudson BD, Kulp KS, Loots GG. Prostate cancer invasion and metastasis: insights from mining genomic data. Briefings in functional genomics. 2013; 12:397-410.
2. Wen X, Deng FM, Wang J. MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer. American journal of clinical and experimental urology. 2014; 2:219-230.
3. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochimica et biophysica acta. 2014; 1845:255-265.
4. Guo F, Parker Kerrigan BC, Yang D, Hu L, Shmulevich I, Sood AK, Xue F, Zhang W. Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymalto-epithelial transitions. Journal of hematology & oncology. 2014; 7:19.
5. Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clinical chemistry. 2011; 57:1366-1375.
6. Thieu W, Tilki D, deVere White RW, Evans CP. The role of microRNA in castration-resistant prostate cancer. Urologic oncology. 2014; 32:517-523.
7. Hassan O, Ahmad A, Sethi S, Sarkar FH. Recent updates on the role of microRNAs in prostate cancer. Journal of hematology & oncology. 2012; 5:9.
8. Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate international. 2013; 1:3-9.
9. Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 2014; 33:135-147.
10. Casanova-Salas I, Rubio-Briones J, Fernandez-Serra A, Lopez-Guerrero JA. miRNAs as biomarkers in prostate cancer. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012; 14:803-811.
11. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW, Kung HJ. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014; 33:2495-2503.
12. Wang L, Li Y, Yang X, Yuan H, Li X, Qi M, Chang YW, Wang C, Fu W, Yang M, Zhang J, Han B. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells. The Prostate. 2014; 74:647-658.
13. Arancio W. A bioinformatics analysis of Lamin-A regulatory network: a perspective on epigenetic involvement in Hutchinson-Gilford progeria syndrome. Rejuvenation research. 2012; 15:123-127.
14. Ye L, Li S, Ye D, Yang D, Yue F, Guo Y, Chen X, Chen F, Zhang J, Song X. Livin expression may be regulated by miR-198 in human prostate cancer cell lines. European journal of cancer. 2013; 49:734-740.
15. Tang Y, Yan W, Chen J, Luo C, Kaipia A, Shen B. Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer. BMC systems biology. 2013; 7:S6.
16. Yang F, Zhang Y, Ressler SJ, Ittmann MM, Ayala GE, Dang TD, Wang F, Rowley DR. FGFR1 is essential for prostate cancer progression and metastasis. Cancer research. 2013; 73:3716-3724.
17. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. The Biochemical journal. 2011; 437:199-213.
18. Cho KH, Jeong KJ, Shin SC, Kang J, Park CG, Lee HY. STAT3 mediates TGF-beta1-induced TWIST1 expression and prostate cancer invasion. Cancer letters. 2013; 336:167-173.
19. Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCgamma/COX-2-mediated mechanisms. PloS one. 2012; 7:e38972.
20. Nguyen PT, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N, Takata T. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. British journal of cancer. 2013; 109:2248-2258.
21. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z. GATA-3 and the regulation of the mammary luminal cell fate. Current opinion in cell biology. 2008; 20:164-170.
22. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! Journal of cellular physiology. 2010; 222:42-49.
23. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nature cell biology. 2013; 15:201-213.
24. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocrine-related cancer. 2010; 17:F1-17.
25. Wang Q, Hui H, Guo Z, Zhang W, Hu Y, He T, Tai Y, Peng P, Wang L. ADAR1 regulates ARHGAP26 gene expression through RNA editing by disrupting miR-30b-3p and miR-573 binding. Rna. 2013; 19:1525-1536.
26. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene. 2000; 19:3309-3320.
27. Kumar SB, Narasu L, Gundla R, Dayam R, J ARPS. Fibroblast growth factor receptor inhibitors. Current pharmaceutical design. 2013; 19:687-701.
28. Nguyen AH, Tremblay M, Haigh K, Koumakpayi IH, Paquet M, Pandolfi PP, Mes-Masson AM, Saad F, Haigh JJ, Bouchard M. Gata3 antagonizes cancer progression in Pten-deficient prostates. Human molecular genetics. 2013; 22:2400-2410.
29. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. The Journal of biological chemistry. 2010; 285:14042-14051.
30. Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Zhang J, Han B. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate cancer and prostatic diseases. 2013; 16:301-307.
31. Wang L, Song G, Chang X, Tan W, Pan J, Zhu X, Liu Z, Qi M, Yu J, Han B. The role of TXNDC5 in castrationresistant prostate cancer-involvement of androgen receptor signaling pathway. Oncogene. 2014.
32. Wang L, Zheng Y, Xu H, Yan X, Chang X. Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis. PloS one. 2013; 8:e53301.